Combined, these results suggest that activation of both subtypes with a β2-β3-AR dual agonist would effectively combat obesity and its related metabolic perturbations, while largely limiting cardiovascular side-effects by avoiding β1-AR stimulation. Here, ADRB3 is linked to obesity due to melanocortin 4 receptor deficiency.